Genmab's Epcoritamab Extends Survival in DLBCL Patients, Stock Drops 7%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Should l Buy ABBV?
Source: seekingalpha
- Clinical Trial Results: Genmab's bispecific antibody Epcoritamab demonstrated potential to extend progression-free survival in late-stage diffuse large B-cell lymphoma (DLBCL) patients in a Phase 3 trial, yet the lack of statistically significant overall survival improvement led to a 7% drop in stock price, reflecting investor concerns.
- Improved Patient Response Rates: In a global trial involving 483 relapsed/refractory DLBCL patients who had undergone at least one prior therapy, Epcoritamab as a monotherapy improved complete response rates and duration of response, indicating its therapeutic potential despite not achieving overall survival significance.
- FDA Accelerated Approval: Epcoritamab is currently available in the U.S. under the FDA's accelerated approval pathway for DLBCL patients who have relapsed or failed to respond to two or more treatments, highlighting its market relevance and potential commercial opportunity.
- Future Regulatory Discussions: Genmab plans to meet with global regulators to discuss next steps for the program, demonstrating the company's commitment to further developing Epcoritamab, even as current clinical results fell short of market expectations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 233.860
Low
223.00
Averages
252.00
High
289.00
Current: 233.860
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Achieves Over $1 Billion Sales for 10 Therapies in 2025
- Sales Growth: In 2025, AbbVie achieved over $1 billion in annual sales for 10 therapies, with total revenue reaching $61.2 billion, reflecting a robust 8.6% growth and underscoring the company's strong market performance and growth potential.
- Dividend Increase: AbbVie has raised its dividend for 54 consecutive years, with a 5.5% increase this year, making it a 'Dividend King', which not only attracts income-focused investors but also enhances the company's stability and appeal in the market.
- R&D Investments: AbbVie made significant acquisitions in 2024, including over $10 billion for ImmunoGen, bolstering its pipeline in oncology and neuroscience, demonstrating its commitment to innovation and responsiveness to market demands.
- FDA Approval: AbbVie received FDA approval to market Venclexta as a first-line treatment for chronic lymphocytic leukemia, which not only enhances the competitiveness of its product portfolio but also lays a foundation for future revenue growth.
See More
AbbVie Successfully Transitions, Revenue Continues to Grow
- Significant Revenue Growth: In 2025, AbbVie's revenue reached $61.2 billion, reflecting an 8.6% increase, despite a 1.3% decline in earnings per share to $2.36 due to R&D and acquisition expenses, demonstrating the company's resilience and growth potential in the pharmaceutical market.
- Robust Product Pipeline: AbbVie currently has over 90 compounds in its pipeline, with two-thirds in mid- to late-stage trials, particularly bolstered by acquisitions of ImmunoGen and Cerevel Therapeutics, enhancing its oncology and neuroscience portfolios, which are expected to drive future revenue growth.
- Consistent Dividend Growth: AbbVie has raised its dividend for 54 consecutive years, with a 5.5% increase this year, yielding approximately 2.8%, significantly higher than the average yield of the S&P 500, showcasing the company's strong capability in delivering shareholder returns.
- Long-Term Management Strategy: AbbVie's management focuses on long-term growth, maintaining strong demand for its oncology, immunology, and psychiatric medications despite economic fluctuations, achieving a gross margin of 72.6%, ensuring ample funding for R&D and dividend payments.
See More
Xiaomi Trials Humanoid Robots to Boost Productivity
- Productivity Enhancement: Xiaomi is trialing humanoid robots in its electric vehicle production lines, with two robots completing 90% of tasks in three hours, significantly boosting efficiency and indicating the company's proactive exploration of automation.
- Technical Challenges Addressed: The company's president noted that the robots must keep pace with a new car rolling off the assembly line every 76 seconds, demonstrating Xiaomi's commitment and challenges in integrating robotic technology into production processes.
- Future Outlook: Xiaomi plans to enable humanoid robots to replace certain human tasks and accomplish work traditionally beyond human capability, signaling the company's long-term strategy in smart manufacturing.
- Market Potential: Analysts forecast a global humanoid robot market of $9 trillion by 2050, with China accounting for over 60%, highlighting Xiaomi's strategic foresight in this rapidly growing market.
See More
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
AbbVie: A Strong Dividend Investment Choice
- Dividend Yield Advantage: AbbVie offers a dividend yield of 2.9%, significantly higher than the S&P 500's 1.1%, making it an attractive choice for long-term investors seeking steady cash flow for their portfolios.
- Consistent Dividend Growth: Since its inception in 2013, AbbVie has increased its dividend by over 330%, which not only boosts investor confidence but also indicates the company's capability to combat inflation effectively.
- Strong Cash Flow: Despite a payout ratio exceeding 100%, AbbVie reported a free cash flow of $17.8 billion last year, far surpassing the $11.7 billion paid in dividends, demonstrating its robust financial health.
- Diverse Growth Opportunities: AbbVie has a rich product portfolio across oncology, neuroscience, aesthetics, eye care, and immunology, with projected net revenue of $61.2 billion by 2025, showcasing its strong growth potential.
See More
AbbVie Increases Dividend by Over 330% Since IPO
- Significant Dividend Growth: AbbVie has increased its dividend by over 330% since its IPO in 2013, currently offering a yield of 2.9%, which is substantially higher than the S&P 500 average of 1.1%, indicating the company's stability and growth potential in dividend payments.
- Strong Cash Flow Support: Last year, AbbVie generated $17.8 billion in free cash flow, significantly exceeding its $11.7 billion in dividend payments, which, despite a payout ratio over 100%, demonstrates robust cash flow capabilities for sustaining dividends.
- Diverse Growth Opportunities: AbbVie has a rich product portfolio across oncology, neuroscience, aesthetics, eye care, and immunology, with projected net revenue of $61.2 billion and a growth rate of 9% by 2025, showcasing its ability to continuously develop new drugs and acquire companies.
- Enhanced Investor Confidence: Although AbbVie was not included in the current top investment stocks identified by analysts, its stable dividend and strong growth prospects make it an ideal choice for long-term investors, providing a reliable cash flow for their portfolios.
See More
AbbVie Achieves Over $1 Billion Sales for 10 Therapies in 2025
- Sales Growth: In 2025, AbbVie achieved over $1 billion in annual sales for 10 therapies, with total revenue reaching $61.2 billion, reflecting a robust 8.6% growth and underscoring the company's strong market performance and growth potential.
- Dividend Increase: AbbVie has raised its dividend for 54 consecutive years, with a 5.5% increase this year, making it a 'Dividend King', which not only attracts income-focused investors but also enhances the company's stability and appeal in the market.
- R&D Investments: AbbVie made significant acquisitions in 2024, including over $10 billion for ImmunoGen, bolstering its pipeline in oncology and neuroscience, demonstrating its commitment to innovation and responsiveness to market demands.
- FDA Approval: AbbVie received FDA approval to market Venclexta as a first-line treatment for chronic lymphocytic leukemia, which not only enhances the competitiveness of its product portfolio but also lays a foundation for future revenue growth.
See More
AbbVie Successfully Transitions, Revenue Continues to Grow
- Significant Revenue Growth: In 2025, AbbVie's revenue reached $61.2 billion, reflecting an 8.6% increase, despite a 1.3% decline in earnings per share to $2.36 due to R&D and acquisition expenses, demonstrating the company's resilience and growth potential in the pharmaceutical market.
- Robust Product Pipeline: AbbVie currently has over 90 compounds in its pipeline, with two-thirds in mid- to late-stage trials, particularly bolstered by acquisitions of ImmunoGen and Cerevel Therapeutics, enhancing its oncology and neuroscience portfolios, which are expected to drive future revenue growth.
- Consistent Dividend Growth: AbbVie has raised its dividend for 54 consecutive years, with a 5.5% increase this year, yielding approximately 2.8%, significantly higher than the average yield of the S&P 500, showcasing the company's strong capability in delivering shareholder returns.
- Long-Term Management Strategy: AbbVie's management focuses on long-term growth, maintaining strong demand for its oncology, immunology, and psychiatric medications despite economic fluctuations, achieving a gross margin of 72.6%, ensuring ample funding for R&D and dividend payments.
See More
Xiaomi Trials Humanoid Robots to Boost Productivity
- Productivity Enhancement: Xiaomi is trialing humanoid robots in its electric vehicle production lines, with two robots completing 90% of tasks in three hours, significantly boosting efficiency and indicating the company's proactive exploration of automation.
- Technical Challenges Addressed: The company's president noted that the robots must keep pace with a new car rolling off the assembly line every 76 seconds, demonstrating Xiaomi's commitment and challenges in integrating robotic technology into production processes.
- Future Outlook: Xiaomi plans to enable humanoid robots to replace certain human tasks and accomplish work traditionally beyond human capability, signaling the company's long-term strategy in smart manufacturing.
- Market Potential: Analysts forecast a global humanoid robot market of $9 trillion by 2050, with China accounting for over 60%, highlighting Xiaomi's strategic foresight in this rapidly growing market.
See More
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
AbbVie: A Strong Dividend Investment Choice
- Dividend Yield Advantage: AbbVie offers a dividend yield of 2.9%, significantly higher than the S&P 500's 1.1%, making it an attractive choice for long-term investors seeking steady cash flow for their portfolios.
- Consistent Dividend Growth: Since its inception in 2013, AbbVie has increased its dividend by over 330%, which not only boosts investor confidence but also indicates the company's capability to combat inflation effectively.
- Strong Cash Flow: Despite a payout ratio exceeding 100%, AbbVie reported a free cash flow of $17.8 billion last year, far surpassing the $11.7 billion paid in dividends, demonstrating its robust financial health.
- Diverse Growth Opportunities: AbbVie has a rich product portfolio across oncology, neuroscience, aesthetics, eye care, and immunology, with projected net revenue of $61.2 billion by 2025, showcasing its strong growth potential.
See More
AbbVie Increases Dividend by Over 330% Since IPO
- Significant Dividend Growth: AbbVie has increased its dividend by over 330% since its IPO in 2013, currently offering a yield of 2.9%, which is substantially higher than the S&P 500 average of 1.1%, indicating the company's stability and growth potential in dividend payments.
- Strong Cash Flow Support: Last year, AbbVie generated $17.8 billion in free cash flow, significantly exceeding its $11.7 billion in dividend payments, which, despite a payout ratio over 100%, demonstrates robust cash flow capabilities for sustaining dividends.
- Diverse Growth Opportunities: AbbVie has a rich product portfolio across oncology, neuroscience, aesthetics, eye care, and immunology, with projected net revenue of $61.2 billion and a growth rate of 9% by 2025, showcasing its ability to continuously develop new drugs and acquire companies.
- Enhanced Investor Confidence: Although AbbVie was not included in the current top investment stocks identified by analysts, its stable dividend and strong growth prospects make it an ideal choice for long-term investors, providing a reliable cash flow for their portfolios.
See More
